MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dementia with Lewy bodies (DLB)"

  • 2018 International Congress

    Angiotensin-converting enzyme inhibitors are neuroprotective regarding APOE-mediated motor and non-motor experiences for Alzheimer’s dementia but not for dementia with Lewy bodies

    F. Oliveira, M. Miraldo, E. Castro-Neto, F. Machado, S. Almeida, S. Matas, P. Bertolucci, M. Naffah-Mazzacoratti (São Paulo, Brazil)

    Objective: To assess whether angiotensin-converting enzyme (ACE) inhibitors modulate associations of biofluid concentrations and activity of ACE with motor and non-motor experiences in dementia with…
  • 2018 International Congress

    Dual task walking differentially affects toe clearance in Lewy body disease: A contributor to dynamic falls risk?

    L. Alcock, R. McArdle, L. Aubrook, B. Galna, A. Thomas, L. Rochester (Newcastle upon Tyne, United Kingdom)

    Objective: To evaluate the change in gait and minimum toe clearance when walking under dual task in different dementia sub-types as a contributor to dynamic…
  • 2018 International Congress

    Efficacy and safety of Rasagiline in treatment of gait disturbances in dementia with Lewy bodies

    A. Chimagomedova, O. Levin, M. Anikina, I. Ayzenberg (Moscow, Russian Federation)

    Objective: We aimed to investigate the efficacy and safety of rasagiline in addition to levodopa in patients with dementia with Lewy bodies (DLB). Background: Management…
  • 2018 International Congress

    Insulin degrading enzyme, a novel key protein against alpha-synuclein oligomers formation?

    I. Martinez-Valbuena, R. Valenti-Azcarate, I. Amat-Villegas, I. Marcilla-Garcia, L. Alonso-Herrero, M. Carmona-Abellan, G. Marti-Andres, MT. Tuñon-Alvarez, MR. Luquin-Piudo (Pamplona, Spain)

    Objective: The objective of this work is to study the interaction between α-synuclein and the insulin degrading enzyme in the pancreas of subjects with synucleinopathies.…
  • 2017 International Congress

    Improved diagnosis of dementia with Lewy bodies by the combination of Tc-99m ECD SPECT with eZIS analysis and quantitative TRODAT-1 SPECT images

    C.-Y. Wei, P.-Y. Chiu (Changhua County, Taiwan)

    Objective: The development of easily useful neuroimaging may resolve to the delays of diagnosis. Background: Dementia with Lewy bodies (DLB) is easy to be misdiagnosed…
  • 2017 International Congress

    Voxel-based Analysis of Cholinesterase Inhibitor Response in Lewy Body Disorders: A Prospective Observational Study

    J. Compagnone, H. Mustaerts, J. Li, M. Freedman, K. Galit, J. Lee, J. Kennedy, R. Chen, D. Tang-Wai, A. Lang, N. Herrmann, S. Black, M. Masellis (Toronto, ON, Canada)

    Objective: The objective is to investigate functional neuroimaging correlates of response to ChEIs in LBD. Background: Lewy body disorders (LBD), including dementia with Lewy bodies…
  • 2017 International Congress

    Defective visual perception in patients with Lewy body disease: assessment of hallucinations with pareidolia test.

    Y. Higashi, T. Tabuchi, M. Tabata (Himeji, Japan)

    Objective: Hallucination is a common feature in patients with advanced Parkinson’s disease(PD) and dementia with Lewy bodies (DLB). Background: The pareidolia test is a tool…
  • 2017 International Congress

    Feasibility, tolerability and acceptance of a psychosocial intervention for people with Parkinsonian dementia: The INVEST trial.

    S. McCormick, K. McDonald, S. Vatter, V. Orgeta, E. Poliakoff, S. Smith, M. Silverdale, B. Fu, I. Leroi (Manchester, United Kingdom)

    Objective: To compare a companion-guided, home-delivered psychosocial stimulation intervention to treatment as usual (TAU) to inform a large-scale efficacy trial for people with cognitive impairment…
  • 2017 International Congress

    A new psychosocial intervention for people with Parkinsonian dementias: Adherence, barriers and facilitators

    S. McCormick, K. McDonald, S. Vatter, V. Orgeta, E. Poliakoff, S. Smith, M. Silverdale, B. Fu, I. Leroi (Manchester, United Kingdom)

    Objective: To investigate participant adherence and engagement to a home-based, companion-guided cognitive stimulation therapy adapted for people with Parkinsonian dementias (CST-PD). Background: Adherence to rehabilitation…
  • 2017 International Congress

    Do Acetylcholinesterase Inhibitors (AChEI) delay institutionalisation in Parkinson’s and Lewy Body Disease?

    L. Brown, B. Mohamed, E. Thomas (Cardiff, United Kingdom)

    Objective: We explored the use of Rivastigmine in Parkinson’s and Lewy body dementia through assessment of quantitative data obtained from a clinical database. We focussed…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 23
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley